Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
3
Neutral
8
Bullish
3
Bearish
11
Neutral
8
Bullish
27
Bearish
8
Neutral
0
Bullish
24
Discovery themes featuring this stock
Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs).
In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid.
The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability.
Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products.
Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,11,725 Cr
Low Risk
28.8
34.1
1.9
3.2
1,672.20
1,165.55
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stockCipla Ltd (CIPLA) is currently trading at 1,388.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs). In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid. The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability. Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products. Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.
Over the past 52 weeks, Cipla Ltd has traded between a low of ₹1,165.55 and a high of ₹1,672.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Cipla Ltd has a market capitalization of approximately 1,11,725.01. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Cipla Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.80 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,11,725.01 Cr, Cipla Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Cipla Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Cipla Ltd is 28.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
They sold a combined 1.72% stake in Cipla, totaling 1.39 crore shares, based on NSE block deal data cited in reports.
Cipla said the USFDA classified the inspection of its manufacturing facility in Verna, Goa as Voluntary Action Indicated (VAI), communicated on June 10, 2026.
The move was driven by largely positive brokerage commentary that highlighted India’s 15% growth, pipeline visibility, and expectations of improved US launches and earnings visibility.
The stock reacted to management’s FY27 guidance, including 18%-20% EBITDA margin guidance, expectations of double-digit India revenue growth, and a higher US sales run-rate target by end-FY27.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1383.00 | 1,11,725 Cr | 28.80 | 3.24 | 0.94 | 11.27 | 14.95 | 9.11 | ||
1105.65 | 1,11,254 Cr | 22.07 | 4.10 | 0.09 | 18.59 | 17.35 | 9.59 | ||
1275.05 | 1,06,424 Cr | 25.36 | 2.81 | 0.63 | 11.07 | 12.54 | 7.15 | ||
2275.00 | 1,03,975 Cr | 19.50 | 4.63 | 0.79 | 23.76 | 24.88 | 13.96 | ||
2382.00 | 97,948 Cr | 51.20 | 6.01 | 0.04 | 11.74 | 13.13 | 6.90 | ||
1462.65 | 85,035 Cr | 24.26 | 2.24 | 0.00 | 9.25 | 11.76 | 5.99 | ||
1393.00 | 75,122 Cr | 84.52 | 14.17 | 0.14 | 16.77 | 16.14 | 8.47 | ||
| Median: 7 Co. | — | 1393.00 | 1,03,975 Cr | 25.36 | 4.10 | 0.14 | 11.74 | 14.95 | 8.47 |
Regulatory Inspection
USFDA has classified its routine cGMP and Pre-Approval Inspection at Cipla's Verna (Goa) manufacturing facility (conducted 6–17 Apr 2026) as Voluntary Action Indicated (VAI) per USFDA communication dated 10 Jun 2026.
Dividend TDS Communication
Cipla notifies shareholders that the Board recommended final dividend of ₹13/share for FY2025-26 is taxable; shareholders must submit documents to claim nil/lower TDS by 15 June 2026 (PAN as of 5 June 2026 applies).
Dividend tax notice
Cipla notifies shareholders that the Board has recommended a final dividend of ₹13.00 per share for FY2025-26; tax will be deducted at source and shareholders seeking nil/lower TDS must submit requisite documents by 15 June 2026 via the provided portal.
